Is Immunic Stock a Good Investment?
Immunic Investment Advice | IMUX |
- Examine Immunic's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immunic's leadership team and their track record. Good management can help Immunic navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immunic's business and its evolving consumer preferences.
- Compare Immunic's performance and market position to its competitors. Analyze how Immunic is positioned in terms of product offerings, innovation, and market share.
- Check if Immunic pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immunic's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immunic stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immunic is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Immunic Stock
Researching Immunic's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 65.0% of the company shares are owned by institutional investors. The book value of Immunic was currently reported as 0.46. The company recorded a loss per share of 1.23. Immunic last dividend was issued on the 15th of April 2019. The entity had 1:40 split on the 15th of April 2019.
To determine if Immunic is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunic's research are outlined below:
| Immunic generated a negative expected return over the last 90 days | |
| Immunic may become a speculative penny stock | |
| Immunic has high historical volatility and very poor performance | |
| Net Loss for the year was (93.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (70.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Immunic, Inc. to Participate in Investor Conference in December |
Immunic uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunic. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunic's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Immunic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Immunic's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.26 | -0.3 | -0.04 | 15 | ||
2023-05-11 | 2023-03-31 | -0.52 | -0.58 | -0.06 | 11 | ||
2020-11-05 | 2020-09-30 | -0.63 | -0.7 | -0.07 | 11 | ||
2021-02-26 | 2020-12-31 | -0.6 | -0.46 | 0.14 | 23 | ||
2021-08-06 | 2021-06-30 | -0.67 | -0.82 | -0.15 | 22 | ||
2019-11-07 | 2019-09-30 | -0.67 | -0.82 | -0.15 | 22 | ||
2020-05-08 | 2020-03-31 | -0.95 | -0.79 | 0.16 | 16 | ||
2020-03-16 | 2019-12-31 | -0.76 | -0.56 | 0.2 | 26 |
Know Immunic's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 679.3 K | Ikarian Capital, Llc | 2024-09-30 | 493.5 K | Boothbay Fund Management, Llc | 2024-09-30 | 423.5 K | Renaissance Technologies Corp | 2024-09-30 | 389.1 K | Bank Of Montreal | 2024-06-30 | 284.1 K | Bmo Capital Markets Corp. | 2024-06-30 | 284.1 K | Two Sigma Investments Llc | 2024-09-30 | 262.9 K | Citadel Advisors Llc | 2024-09-30 | 240.1 K | Northern Trust Corp | 2024-09-30 | 231.6 K | Bvf Inc | 2024-09-30 | 8.9 M | Avidity Partners Management Lp | 2024-09-30 | 8.3 M |
Immunic's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 102.69 M.Market Cap |
|
Immunic's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.72) | (1.81) | |
| Return On Capital Employed | (3.36) | (3.19) | |
| Return On Assets | (1.72) | (1.64) | |
| Return On Equity | (3.24) | (3.07) |
Determining Immunic's profitability involves analyzing its financial statements and using various financial metrics to determine if Immunic is a good buy. For example, gross profit margin measures Immunic's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunic's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immunic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunic. Check Immunic's Beneish M Score to see the likelihood of Immunic's management manipulating its earnings.
Evaluate Immunic's management efficiency
Immunic has return on total asset (ROA) of (0.909) % which means that it has lost $0.909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1624) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.81 in 2024. Return On Capital Employed is likely to rise to -3.19 in 2024. At this time, Immunic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 70.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.65 | 0.69 | |
| Tangible Book Value Per Share | 0.65 | 0.69 | |
| Enterprise Value Over EBITDA | (0.21) | (0.22) | |
| Price Book Value Ratio | 2.30 | 1.46 | |
| Enterprise Value Multiple | (0.21) | (0.22) | |
| Price Fair Value | 2.30 | 1.46 | |
| Enterprise Value | -69.7 M | -66.2 M |
Immunic benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 1.883 |
Basic technical analysis of Immunic Stock
As of the 27th of November, Immunic retains the Risk Adjusted Performance of (0.04), market risk adjusted performance of (0.15), and Standard Deviation of 4.27. Immunic technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunic's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunic's Outstanding Corporate Bonds
Immunic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunic bonds can be classified according to their maturity, which is the date when Immunic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Immunic's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immunic's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.24 | |||
| Coefficient Of Variation | (1,564) | |||
| Standard Deviation | 4.27 | |||
| Variance | 18.26 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.96) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 23.75 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 6.45 | |||
| Skewness | (0.07) | |||
| Kurtosis | 0.7366 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.24 | |||
| Coefficient Of Variation | (1,564) | |||
| Standard Deviation | 4.27 | |||
| Variance | 18.26 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.96) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 23.75 | |||
| Value At Risk | (6.84) | |||
| Potential Upside | 6.45 | |||
| Skewness | (0.07) | |||
| Kurtosis | 0.7366 |
Consider Immunic's intraday indicators
Immunic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunic time-series forecasting models is one of many Immunic's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immunic Stock media impact
Far too much social signal, news, headlines, and media speculation about Immunic that are available to investors today. That information is available publicly through Immunic media outlets and privately through word of mouth or via Immunic internal channels. However, regardless of the origin, that massive amount of Immunic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunic alpha.
Immunic Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Immunic can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immunic Corporate Management
| Patrick Walsh | Chief Officer | Profile | |
| Glenn CPA | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Inderpal Singh | General Counsel | Profile | |
| Jessica Breu | Head Communications | Profile |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.